{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+III&page=24",
    "query": {
      "condition": "Phase III",
      "page": 24
    },
    "page_size": 10
  },
  "pagination": {
    "page": 24,
    "page_size": 10,
    "total_count": 10486,
    "total_pages": 1049,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+III&page=25&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+III&page=23&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T18:58:41.283Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00389779",
      "title": "DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Darusentan",
          "type": "DRUG"
        },
        {
          "name": "Guanfacine",
          "type": "DRUG"
        },
        {
          "name": "Darusentan Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "35 Years to 80 Years"
      },
      "enrollment_count": 849,
      "start_date": "2006-09",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2014-03-18",
      "last_synced_at": "2026-10-30T18:58:41.283Z",
      "location_count": 87,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 70 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00389779"
    },
    {
      "nct_id": "NCT06698796",
      "title": "A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dermatomyositis",
        "Polymyositis"
      ],
      "interventions": [
        {
          "name": "Dazukibart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 211,
      "start_date": "2025-01-22",
      "completion_date": "2031-07-29",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-30T18:58:41.283Z",
      "location_count": 4,
      "location_summary": "Glendale, Arizona • Frisco, Texas • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Frisco",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Beckley",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06698796"
    },
    {
      "nct_id": "NCT05122546",
      "title": "CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Clear Cell Renal Cell Carcinoma",
        "Advanced Papillary Renal Cell Carcinoma",
        "Advanced Renal Cell Carcinoma",
        "Advanced Sarcomatoid Renal Cell Carcinoma",
        "Metastatic Clear Cell Renal Cell Carcinoma",
        "Metastatic Papillary Renal Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Metastatic Sarcomatoid Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Unresectable Clear Cell Renal Cell Carcinoma",
        "Unresectable Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Clostridium butyricum CBM 588 Probiotic Strain",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2021-11-01",
      "completion_date": "2027-01-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-10-30T18:58:41.283Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05122546"
    },
    {
      "nct_id": "NCT00743288",
      "title": "Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Panobinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2008-07",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2014-05-08",
      "last_synced_at": "2026-10-30T18:58:41.283Z",
      "location_count": 4,
      "location_summary": "Bakersfield, California • West Hollywood, California • Denver, Colorado + 1 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00743288"
    },
    {
      "nct_id": "NCT04964089",
      "title": "A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Wet Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "KSI-301",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Kodiak Sciences Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 557,
      "start_date": "2021-06-23",
      "completion_date": "2023-04-06",
      "has_results": true,
      "last_update_posted_date": "2024-07-03",
      "last_synced_at": "2026-10-30T18:58:41.283Z",
      "location_count": 65,
      "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04964089"
    },
    {
      "nct_id": "NCT03491150",
      "title": "An Open-Label Crenezumab Study in Participants With Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Crenezumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 149,
      "start_date": "2018-04-11",
      "completion_date": "2019-05-31",
      "has_results": true,
      "last_update_posted_date": "2020-07-13",
      "last_synced_at": "2026-10-30T18:58:41.283Z",
      "location_count": 32,
      "location_summary": "Newport Beach, California • Redlands, California • Sacramento, California + 28 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03491150"
    },
    {
      "nct_id": "NCT07013474",
      "title": "A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19 Infection"
      ],
      "interventions": [
        {
          "name": "ibuzatrelvir",
          "type": "DRUG"
        },
        {
          "name": "remdesivir",
          "type": "DRUG"
        },
        {
          "name": "placebo for ibuzatrelvir",
          "type": "DRUG"
        },
        {
          "name": "placebo for remdesivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2025-07-14",
      "completion_date": "2028-02-05",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-30T18:58:41.283Z",
      "location_count": 70,
      "location_summary": "Canoga Park, California • Granada Hills, California • La Jolla, California + 26 more",
      "locations": [
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07013474"
    },
    {
      "nct_id": "NCT00006110",
      "title": "Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "1 Year to 120 Years · Female only"
      },
      "enrollment_count": 82,
      "start_date": "1998-12",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2017-07-31",
      "last_synced_at": "2026-10-30T18:58:41.283Z",
      "location_count": 2,
      "location_summary": "Chapel Hill, North Carolina • Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006110"
    },
    {
      "nct_id": "NCT00847613",
      "title": "A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "CP-690,550",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2009-03",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2024-05-16",
      "last_synced_at": "2026-10-30T18:58:41.283Z",
      "location_count": 37,
      "location_summary": "Huntsville, Alabama • Tucson, Arizona • San Diego, California + 32 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00847613"
    },
    {
      "nct_id": "NCT05361720",
      "title": "Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Clear Cell Renal Cell Carcinoma",
        "Metastatic Clear Cell Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2022-12-06",
      "completion_date": "2028-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-30T18:58:41.283Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Orange, California • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05361720"
    }
  ]
}